Artikel ; Online: Aktualitások a sérült immunitású betegek cytomegalovirusinfekcióinak ellátásában. II. Terápiás lehetőségek és ellátási stratégiák.
2019 Band 160, Heft 10, Seite(n) 363–369
Abstract: Although cytomegalovirus is one of the most prevalent viral pathogens on the globe, in immunocompetent individuals infected with cytomegalovirus usually no specific antiviral therapy is required. In the case of impaired T-cell mediated immunity, however, ...
| Titelübersetzung | Current treatment modalities of immunocompromised patients with cytomegalovirus infection. II. Therapeutic options and management strategies. |
|---|---|
| Abstract | Although cytomegalovirus is one of the most prevalent viral pathogens on the globe, in immunocompetent individuals infected with cytomegalovirus usually no specific antiviral therapy is required. In the case of impaired T-cell mediated immunity, however, latent infection can reactivate and occasionally a viral disease with organ involvement develops. The number of actually available anti-cytomegalovirus drugs is low, for prophylaxis or treatment ganciclovir, valganciclovir, foscarnet or cidofovir can be administered. The clinical use of these drugs is primarily hampered by their toxicity. In search for new treatment options, only letermovir, a terminase complex inhibitor compound showed appropriate activity and tolerability. In a placebo-controlled clinical trial on prophylactic letermovir in stem cell transplant patients, administration of the active compound resulted in a significant decrease in human cytomegalovirus reactivations as well as in prolonged survival. No toxicity affecting clinical use has been observed. For management of patients being at high risk for cytomegalovirus reactivation, appropriate antiviral strategy should be followed. Antiviral prophylaxis or diagnostics-guided pre-emptive therapy seem to be the most suitable options. Orv Hetil. 2019; 160(10): 363-369. |
| Mesh-Begriff(e) | Acetates/administration & dosage ; Acetates/therapeutic use ; Acyclovir/therapeutic use ; Antiviral Agents/therapeutic use ; Cytomegalovirus/drug effects ; Cytomegalovirus Infections/drug therapy ; Cytomegalovirus Infections/physiopathology ; Cytomegalovirus Infections/prevention & control ; Foscarnet/therapeutic use ; Ganciclovir/therapeutic use ; Humans ; Immunocompromised Host ; Quinazolines/administration & dosage ; Quinazolines/therapeutic use ; Stem Cell Transplantation/adverse effects |
| Chemische Substanzen | Acetates ; Antiviral Agents ; Quinazolines ; AIC246 (1H09Y5WO1F) ; Foscarnet (364P9RVW4X) ; Ganciclovir (P9G3CKZ4P5) ; Acyclovir (X4HES1O11F) |
| Sprache | Ungarisch |
| Erscheinungsdatum | 2019-03-04 |
| Erscheinungsland | Hungary |
| Dokumenttyp | Journal Article ; Review |
| ZDB-ID | 123879-6 |
| ISSN | 1788-6120 ; 0030-6002 |
| ISSN (online) | 1788-6120 |
| ISSN | 0030-6002 |
| DOI | 10.1556/650.2019.31320 |
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Zs.B 301: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.